Limaprost-d3

CAT: 0804-HY-B0683S-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0683S-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Limaprost-d3 (17α,20-dimethyl-δ2-PGE1-d3) is the deuterium labeled Limaprost. Limaprost (OP1206) is a PGE1 analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research[1][2].
CAS Number
[1263190-37-9]
UNSPSC
12352211
Hazard Statement
H300-H315-H319
Target
Isotope-Labeled Compounds; PGE synthase
Type
Isotope-Labeled Compounds
Related Pathways
Immunology/Inflammation; Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Solubility
10 mM in DMSO
Smiles
C(CCCC=CC(O)=O)[C@@H]1[C@@H](C=C[C@H](C[C@H](CCCC)[C@]([2H])([2H])[2H])O)[C@H](O)CC1=O
Molecular Formula
C22H33D3O5
Molecular Weight
383.54
Precautions
P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P405-P501
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Tsuboi T, et al. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther. 1980 Sep;247 (1) :89-102.|[3]Swainston Harrison T, et al. Limaprost. Drugs. 2007;67 (1) :109-18; discussion 119-20.|[4]Murata K, et al. PGE1 Attenuates IL-1β-induced NGF Expression in Human Intervertebral Disc Cells. Spine (Phila Pa 1976) . 2016 Jun;41 (12) :E710-6.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products